# EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

> **NCT03057977** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 3730 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03057977
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-06
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-05-28
- **Target enrollment:** 3730 (ACTUAL)
- **Last updated:** 2021-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057977, "EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03057977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*